Ahead of Exelon (EXC) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics

30.10.25 14:15 Uhr

Werte in diesem Artikel
Aktien

40,44 EUR -0,40 EUR -0,98%

Indizes

PKT PKT

3.531,4 PKT 2,1 PKT 0,06%

25.894,0 PKT -225,8 PKT -0,86%

17.884,5 PKT -174,8 PKT -0,97%

3.456,6 PKT -24,4 PKT -0,70%

6.857,0 PKT -33,6 PKT -0,49%

Wall Street analysts forecast that Exelon (EXC) will report quarterly earnings of $0.76 per share in its upcoming release, pointing to a year-over-year increase of 7%. It is anticipated that revenues will amount to $6.35 billion, exhibiting an increase of 3.2% compared to the year-ago quarter.Over the last 30 days, there has been a downward revision of 7.2% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.Given this perspective, it's time to examine the average forecasts of specific Exelon metrics that are routinely monitored and predicted by Wall Street analysts.The average prediction of analysts places 'Operating revenues- PECO' at $1.12 billion. The estimate indicates a year-over-year change of +8.5%.Analysts forecast 'Operating revenues- ComEd' to reach $2.23 billion. The estimate suggests a change of +0.2% year over year.The consensus among analysts is that 'Operating revenues- PHI' will reach $1.85 billion. The estimate indicates a change of -0.8% from the prior-year quarter.Analysts' assessment points toward 'Operating revenues- BGE' reaching $1.14 billion. The estimate suggests a change of +9.2% year over year.The combined assessment of analysts suggests that 'Electric revenues- ComEd' will likely reach $2.23 billion. The estimate points to a change of +0.2% from the year-ago quarter.Analysts expect 'Electric revenues- ACE' to come in at $490.93 million. The estimate indicates a year-over-year change of -9.1%.It is projected by analysts that the 'Electric revenues- PHI' will reach $1.80 billion. The estimate indicates a year-over-year change of -2.2%.Based on the collective assessment of analysts, 'Natural gas revenues- PHI' should arrive at $36.76 million. The estimate indicates a year-over-year change of +59.8%.Analysts predict that the 'Electric revenues- DPL' will reach $446.27 million. The estimate suggests a change of +1.7% year over year.According to the collective judgment of analysts, 'Natural gas revenues- BGE' should come in at $208.76 million. The estimate indicates a year-over-year change of +100.7%.The collective assessment of analysts points to an estimated 'Natural gas revenues- PECO' of $135.12 million. The estimate indicates a change of +93% from the prior-year quarter.The consensus estimate for 'Electric revenues- BGE' stands at $950.00 million. The estimate points to a change of +2.7% from the year-ago quarter. View all Key Company Metrics for Exelon here>>> Exelon shares have witnessed a change of +4.8% in the past month, in contrast to the Zacks S&P 500 composite's +3.6% move. With a Zacks Rank #3 (Hold), EXC is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .Zacks' Research Chief Picks Stock Most Likely to "At Least Double"Our experts have revealed their Top 5 recommendations with money-doubling potential – and Director of Research Sheraz Mian believes one is superior to the others. Of course, all our picks aren’t winners but this one could far surpass earlier recommendations like Hims & Hers Health, which shot up +209%.See Our Top Stock to Double (Plus 4 Runners Up) >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Exelon Corporation (EXC): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

In eigener Sache

Übrigens: Exelon und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und Neukunden-Bonus sichern!

Ausgewählte Hebelprodukte auf Exelon

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Exelon

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu Exelon Corp.

Wer­bung

Analysen zu Exelon Corp.

DatumRatingAnalyst
13.08.2019Exelon OverweightBarclays Capital
24.07.2018Exelon Sector OutperformScotia Howard Weil
23.01.2018Exelon NeutralMizuho
15.05.2017Exelon BuyUBS AG
13.10.2016Exelon NeutralUBS AG
DatumRatingAnalyst
13.08.2019Exelon OverweightBarclays Capital
24.07.2018Exelon Sector OutperformScotia Howard Weil
15.05.2017Exelon BuyUBS AG
24.03.2016Exelon OverweightBarclays Capital
07.03.2016Exelon BuyArgus Research Company
DatumRatingAnalyst
23.01.2018Exelon NeutralMizuho
13.10.2016Exelon NeutralUBS AG
13.01.2016Exelon NeutralUBS AG
17.11.2015Exelon Sector PerformScotia Howard Weil
26.08.2015Exelon NeutralUBS AG
DatumRatingAnalyst
02.11.2012Exelon sellUBS AG
12.09.2012Exelon sellUBS AG

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Exelon Corp. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen